Ofatumumab is a disease-modifying therapy (DMT) that works by targeting a type of immune cell called a B cell.  It is the first self-administered B-cell targeting therapy to be licensed in the UK.

After initial guidance from a healthcare professional, ofatumumab can be self-injected at home. The licence is based on the results of two Phase III clinical trials, called ASCLEPIOS, which compared ofatumumab to treatment with another existing DMT, teriflunomide (also called Aubagio).

Ofatumumab demonstrated a significant reduction in the number of relapses as compared to teriflunomide. Read on.

Doctors in the UK are to launch a world-first clinical trial to assess whether drugs already on the market can prevent multiple sclerosis (MS) from worsening over time and even reverse the disabilities it causes.

The groundbreaking Octopus trial, so named because of its various arms, will allow researchers to investigate the potential benefits of several drugs at once, in the hope of identifying effective new treatments three times faster than if the medicines were trialled separately.

Hundreds of patients sought for the trial will be randomly assigned to have either standard care for progressive MS or standard care plus one of three drugs that doctors hope will at least protect their neurons from the disease if not repair the damage done.  Read on.

Staying Smart is for people who want to learn more about how MS can affect thinking. Not everyone with MS will experience cognitive difficulties. But for those who do, information can be hard to find.

“Cognition” is the general word that covers all aspects of thinking. It includes memory, concentration and planning.

Cognition problems in everyday life generally fall into one of six types of problem.  Read on. 

If you have not yet been called by your GP surgery, you can book at a vaccination hub near you through the NHS website.

MS is listed in the “clinically vulnerable” category.

Book your covid vaccination here.